This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Prognosis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Patients with sarcoidosis generally have a good prognosis (1).

Some information concerning the prognosis in sarcoidosis is given below:

  • spontaneous remission is seen in
    • 55–90% of patients with stage I radiological disease
    • 40–70% with stage II disease
    • 10–20% with stage III disease
    • 0% in stage IV disease (2).
  • In majority of patients remission occurs within the first 6 months (2)
  • the disease wax and wane (can be spontaneous or after treatment)
  • adverse prognosis is seen in patients with
    • those aged 40 or more at onset
    • black patients
    • lupus pernio
    • chronic uveitis
    • chronic hepercalcaemia
    • nephrocalcinosis
    • progressive pulmonary sarcoidosis
    • cystic bone lesions
    • neurosarcoidosis
    • myocardial involvement (1,2)
  • HLA-B13 and HLA-D27 appear to be markers of more chronic disease
  • overall mortality in sarcoidosis is estimated to be around 1–5% , majority are due to pulmonary, myocardial or CNS involvement (3)
  • as many as 10% will become disabled by pulmonary fibrosis

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.